We ignite innovation through AI and biomarkers

Linearis Labs and Linearis Ventures | Our Mission

Through Linearis Labs’ identification of multi-omics disease signatures and through the capital generated via Linearis Labs, we will amplify the innovation cycle of diagnostics, treatment monitoring and AI drug discovery companies.

Linearis Labs couples high throughput technology and mass spectrometry to provide metabolomics analysis of blood plasma or serum for diseases including cancer, diabetes and infectious diseases which have significant metabolomics components.

Using an AI pipeline, disease signatures are discovered and can provide staging of several types of metabolomic diseases (cancer, diabetes, infectious diseases), the effectiveness of therapeutic interventions, and the emergence of resistance and side effects of treatments.

Linearis Labs offers metabolomics profiling services. Services include both targeted and untargeted LC-MS measurements. High throughput procedures are also available to process thousands of samples using laser diode thermal desorption mass spectrometry. The analyses are carried out in a certified environment and are of clinical quality.

The data is made available in an AI-friendly format for machine learning-based analysis. Linearis Labs can also perform data analysis with state-of-the-art machine learning algorithms.

As metabolomics is closer to the phenotype of interest, it is a great advantage for biobanks to acquire metabolomics data (e.g. UK Biobank). Moreover, there is now an expectation that multi-omics analyses will be available for publication and for better interpretation of the diseases under analysis.

Linearis Ventures, the responsible AI health fund, is an evergreen fund that provides access to capital and disease signatures in Cancer, AMR and Diabetes to facilitate diagnosis, monitoring treatment and improve drug discovery for our partners.